Search
Oxprenolol
go.drugbank.com/drugs/DB01580ApprovedWithdrawnA beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
Levobetaxolol
go.drugbank.com/drugs/DB09351ApprovedLevobetaxolol is a beta-blocker used to lower the pressure in the eye to treat conditions such as glaucoma. It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.
Sinecatechins
go.drugbank.com/drugs/DB01266ApprovedInvestigationalNutraceuticalSinecatechins is a botanical drug product for topical use.
Teprasiran
go.drugbank.com/drugs/DB15064InvestigationalTeprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).
Piclamilast
go.drugbank.com/drugs/DB01791ExperimentalPiclamilast (RP-73,401), is a selective PDE4 inhibitor comparable to other PDE4 inhibitors for its anti-inflammatory effects. … It has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma.
Formebolone
go.drugbank.com/drugs/DB01569IllicitInvestigational[A14416] Additionally, it has been patented for use in development of novel transdermal delivery systems for enhanced drug delivery. … It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.
Navarixin
go.drugbank.com/drugs/DB11711InvestigationalNavarixin has been investigated for the treatment of Asthma.
Sarcosine
go.drugbank.com/drugs/DB12519InvestigationalSarcosine has been investigated for the treatment of Schizophrenia.
Pyronaridine
go.drugbank.com/drugs/DB12975InvestigationalPyronaridine has been investigated for the treatment of Malaria.
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalPhenserine is a next generation acetylcholinesterase (AChE) inhibitor indicated for the treatment of AD. … Phenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia.